Musings from The Power List: Andres Sirulnik
October 5, 2026
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
4 min read
False
Advertisement
Top Stories
Browse By Topic
Newsletters
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.
Voices in the Community
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
View ProfileMusings from The Power List: Claudia Zylberberg
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
Latest News
All the latest Medicine Maker articles.
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
September 30, 2026
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
2 min read
How Companion Diagnostics Can Support Targeted Drug Launches
September 29, 2026
Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval
5 min read
Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
Musings from The Power List: Renee Aguiar-Lucander
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
Roving Reporter Asks: Is Cell and Gene Therapy Entering a More Mature Phase?
September 25, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the regulatory, manufacturing, investment, and commercialization trends signaling a new phase for advanced therapies
1 min read
MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models
September 24, 2026
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
2 min read
Advanced Therapies: Invention or Innovation?
September 23, 2026
Scientific breakthroughs are only true innovations if healthcare systems can deliver them safely, manage their toxicities, and make them accessible at scale
6 min read
“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting
September 23, 2026
Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors
2 min read
Musings from The Power List: Michael May
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
The Barriers Limiting Radiopharmaceutical Access
September 21, 2026
From isotope supply to reimbursement, the practical challenges shaping real-world delivery in oncology
5 min read
Newsletters
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.